Gene-centric functional dissection of human genetic variation uncovers regulators of hematopoiesis

  1. Satish K Nandakumar
  2. Sean K McFarland
  3. Laura Marlene Mateyka
  4. Caleb A Lareau
  5. Jacob C Ulirsch
  6. Leif S Ludwig
  7. Gaurav Agarwal
  8. Jesse M Engreitz
  9. Bartlomiej Przychodzen
  10. Marie McConkey
  11. Glenn S Cowley
  12. John G Doench
  13. Jaroslaw P Maciejewski
  14. Benjamin L Ebert
  15. David E Root
  16. Vijay G Sankaran  Is a corresponding author
  1. Boston Children's Hospital, United States
  2. Broad Institute of MIT and Harvard, United States
  3. Cleveland Clinic, United States
  4. Brigham and Women's Hospital, United States
  5. Broad Institute of Harvard and MIT, United States

Abstract

Genome-wide association studies (GWAS) have identified thousands of variants associated with human diseases and traits. However, the majority of GWAS-implicated variants are in non-coding regions of the genome and require in depth follow-up to identify target genes and decipher biological mechanisms. Here, rather than focusing on causal variants, we have undertaken a pooled loss-of-function screen in primary hematopoietic cells to interrogate 389 candidate genes contained in 75 loci associated with red blood cell traits. Using this approach, we identify 77 genes at 38 GWAS loci, with most loci harboring 1-2 candidate genes. Importantly, the hit set was strongly enriched for genes validated through orthogonal genetic approaches. Genes identified by this approach are enriched in specific and relevant biological pathways, allowing regulators of human erythropoiesis and modifiers of blood diseases to be defined. More generally, this functional screen provides a paradigm for gene-centric follow up of GWAS for a variety of human diseases and traits.

Data availability

1000 Genomes human variation datasetThe 1000 Genomes Project Consortium. (2015)Recombinant hotspots access at:ftp://ftp-trace.ncbi.nih.gov/1000genomes/ftp/pilot_data/technical/reference/Phase 1 data (for PLINK) accessed at: https://www.cog-genomics.org/plink/1.9/resourcesPhase 3 data accessed at: http://www.internationalgenome.org/category/phase-3/Pooled screen abundance data for shRNA targeting red blood cell trait GWAS-nominated genes during the course of in vitro differentiation of human CD34+ cellsSK Nandakumar, SK McFarland, et al. (2019)Available on the project's companion GitHub repository: https://github.com/sankaranlab/shRNA_screen/tree/master/ref/shref.csvEffects of shRNA knockdown of SF3A2 on splicing during human erythropoiesisSK Nandakumar, SK McFarland, et al. (2019)ID GSE129603. In the public domain at GEO https://www.ncbi.nlm.nih.gov/geo/Effects of SF3B1 mutants on splicing in human erythropoiesisEA Obeng et al. (2016)ID GSE85712. In the public domain at GEO https://www.ncbi.nlm.nih.gov/geo/SNP sets identified by GWAS of LDL, HDL, and triglyceride traitsCJ Willer et al. (2013)Accessed at: http://csg.sph.umich.edu/willer/public/lipids2013/Human hematopoietic lineage gene expressionMR Corces et al. (2016)ID GSE74912. In the public domain at GEO https://www.ncbi.nlm.nih.gov/geo/Human adult and fetal erythropoiesis gene expressionH Yan et al. (2018)ID GSE107218. In the public domain at GEO https://www.ncbi.nlm.nih.gov/geo/

Article and author information

Author details

  1. Satish K Nandakumar

    Division of Hematology/Oncology, Boston Children's Hospital, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Sean K McFarland

    Division of Hematology/Oncology, Boston Children's Hospital, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Laura Marlene Mateyka

    Division of Hematology/Oncology, Boston Children's Hospital, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Caleb A Lareau

    Division of Hematology/Oncology, Boston Children's Hospital, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4179-4807
  5. Jacob C Ulirsch

    Division of Hematology/Oncology, Boston Children's Hospital, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Leif S Ludwig

    Division of Hematology/Oncology, Boston Children's Hospital, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Gaurav Agarwal

    Division of Hematology/Oncology, Boston Children's Hospital, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Jesse M Engreitz

    Broad Institute of MIT and Harvard, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5754-1719
  9. Bartlomiej Przychodzen

    Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Marie McConkey

    Division of Hematology, Brigham and Women's Hospital, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Glenn S Cowley

    Broad Institute of MIT and Harvard, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. John G Doench

    Broad Institute of MIT and Harvard, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3707-9889
  13. Jaroslaw P Maciejewski

    Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States
    Competing interests
    The authors declare that no competing interests exist.
  14. Benjamin L Ebert

    Division of Hematology, Brigham and Women's Hospital, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  15. David E Root

    Broad Institute of Harvard and MIT, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  16. Vijay G Sankaran

    Division of Hematology/Oncology, Boston Children's Hospital, Boston, United States
    For correspondence
    sankaran@broadinstitute.org
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0044-443X

Funding

National Institutes of Health (R33HL120791)

  • Vijay G Sankaran

New York Stem Cell Foundation

  • Vijay G Sankaran

National Institutes of Health (R01DK103794)

  • Vijay G Sankaran

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: No human subjects were involved in the study. Human CD34+ HSPCs used in these experiments are deidentified and obtained from external sources. All mouse experiments were performed in full compliance with the approved Institutional Animal Care and Use Committee (IACUC) protocols at Boston Children's Hospital (Protocol # 18-05-3680R) and Brigham and Women's Hospital (Protocol # 2017N000060). These studies were approved by local regulatory committees in accordance with the highest ethical standards for biomedical research involving vertebrate animals.

Copyright

© 2019, Nandakumar et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,857
    views
  • 435
    downloads
  • 14
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Satish K Nandakumar
  2. Sean K McFarland
  3. Laura Marlene Mateyka
  4. Caleb A Lareau
  5. Jacob C Ulirsch
  6. Leif S Ludwig
  7. Gaurav Agarwal
  8. Jesse M Engreitz
  9. Bartlomiej Przychodzen
  10. Marie McConkey
  11. Glenn S Cowley
  12. John G Doench
  13. Jaroslaw P Maciejewski
  14. Benjamin L Ebert
  15. David E Root
  16. Vijay G Sankaran
(2019)
Gene-centric functional dissection of human genetic variation uncovers regulators of hematopoiesis
eLife 8:e44080.
https://doi.org/10.7554/eLife.44080

Share this article

https://doi.org/10.7554/eLife.44080

Further reading

    1. Genetics and Genomics
    2. Microbiology and Infectious Disease
    Dániel Molnár, Éva Viola Surányi ... Judit Toth
    Research Article

    The sustained success of Mycobacterium tuberculosis as a pathogen arises from its ability to persist within macrophages for extended periods and its limited responsiveness to antibiotics. Furthermore, the high incidence of resistance to the few available antituberculosis drugs is a significant concern, especially since the driving forces of the emergence of drug resistance are not clear. Drug-resistant strains of Mycobacterium tuberculosis can emerge through de novo mutations, however, mycobacterial mutation rates are low. To unravel the effects of antibiotic pressure on genome stability, we determined the genetic variability, phenotypic tolerance, DNA repair system activation, and dNTP pool upon treatment with current antibiotics using Mycobacterium smegmatis. Whole-genome sequencing revealed no significant increase in mutation rates after prolonged exposure to first-line antibiotics. However, the phenotypic fluctuation assay indicated rapid adaptation to antibiotics mediated by non-genetic factors. The upregulation of DNA repair genes, measured using qPCR, suggests that genomic integrity may be maintained through the activation of specific DNA repair pathways. Our results, indicating that antibiotic exposure does not result in de novo adaptive mutagenesis under laboratory conditions, do not lend support to the model suggesting antibiotic resistance development through drug pressure-induced microevolution.

    1. Developmental Biology
    2. Genetics and Genomics
    Ignacy Czajewski, Bijayalaxmi Swain ... Daan MF van Aalten
    Research Article

    O-GlcNAcylation is an essential intracellular protein modification mediated by O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA). Recently, missense mutations in OGT have been linked to intellectual disability, indicating that this modification is important for the development and functioning of the nervous system. However, the processes that are most sensitive to perturbations in O-GlcNAcylation remain to be identified. Here, we uncover quantifiable phenotypes in the fruit fly Drosophila melanogaster carrying a patient-derived OGT mutation in the catalytic domain. Hypo-O-GlcNAcylation leads to defects in synaptogenesis and reduced sleep stability. Both these phenotypes can be partially rescued by genetically or chemically targeting OGA, suggesting that a balance of OGT/OGA activity is required for normal neuronal development and function.